BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12029547)

  • 1. [99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results.
    Maina T; Nock B; Nikolopoulou A; Sotiriou P; Loudos G; Maintas D; Cordopatis P; Chiotellis E
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):742-53. PubMed ID: 12029547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.
    Maina T; Nock BA; Cordopatis P; Bernard BF; Breeman WA; van Gameren A; van den Berg R; Reubi JC; Krenning EP; de Jong M
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):831-40. PubMed ID: 16568203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy.
    Gabriel M; Decristoforo C; Maina T; Nock B; vonGuggenberg E; Cordopatis P; Moncayo R
    Cancer Biother Radiopharm; 2004 Feb; 19(1):73-9. PubMed ID: 15068614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetraamine-modified octreotide and octreotate: labeling with 99mTc and preclinical comparison in AR4-2J cells and AR4-2J tumor-bearing mice.
    Nikolopoulou A; Maina T; Sotiriou P; Cordopatis P; Nock BA
    J Pept Sci; 2006 Feb; 12(2):124-31. PubMed ID: 16059963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study.
    Decristoforo C; Maina T; Nock B; Gabriel M; Cordopatis P; Moncayo R
    Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1211-9. PubMed ID: 12845487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
    Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and (94m)Tc-Demotate 1.
    Rogers BE; Parry JJ; Andrews R; Cordopatis P; Nock BA; Maina T
    J Nucl Med; 2005 Nov; 46(11):1889-97. PubMed ID: 16269604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 99mTc demotate 1: biodistribution and elimination characteristics in rats.
    Kopecky M; Trejtnar F; Laznicek M; Laznickova A; Semecky V; Maina T; Nock B
    Nucl Med Commun; 2005 Jun; 26(6):549-54. PubMed ID: 15891599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
    Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging.
    Nock B; Nikolopoulou A; Chiotellis E; Loudos G; Maintas D; Reubi JC; Maina T
    Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):247-58. PubMed ID: 12552343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 99mTc targeting of Sst2-expressing tumors by tetraamineoctreotide: first results in CA20948 cells and rat models.
    Nikolopoulou A; Nock BA; Maina T
    Anticancer Res; 2006; 26(1A):363-6. PubMed ID: 16475719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.
    Decristoforo C; Melendez-Alafort L; Sosabowski JK; Mather SJ
    J Nucl Med; 2000 Jun; 41(6):1114-9. PubMed ID: 10855644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.
    de Jong M; Breeman WA; Bakker WH; Kooij PP; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt MA; Erion JL; Bugaj JE; Mäcke HR; Krenning EP
    Cancer Res; 1998 Feb; 58(3):437-41. PubMed ID: 9458086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, radiolabeling, and preclinical evaluation of a new octreotide analog for somatostatin receptor-positive tumor scintigraphy.
    De K; Bhowmik A; Behera A; Banerjee I; Ghosh MK; Misra M
    J Pept Sci; 2012 Dec; 18(12):720-30. PubMed ID: 23109400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ 219-387) labelled with technetium-99m.
    Maina T; Stolz B; Albert R; Bruns C; Koch P; Mäcke H
    Eur J Nucl Med; 1994 May; 21(5):437-44. PubMed ID: 8062850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors.
    Gandomkar M; Najafi R; Shafiei M; Mazidi M; Ebrahimi SE
    Nucl Med Biol; 2007 Aug; 34(6):651-7. PubMed ID: 17707805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.
    Ugur O; Kothari PJ; Finn RD; Zanzonico P; Ruan S; Guenther I; Maecke HR; Larson SM
    Nucl Med Biol; 2002 Feb; 29(2):147-57. PubMed ID: 11823119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate.
    Wang Q; Graham K; Schauer T; Fietz T; Mohammed A; Liu X; Hoffend J; Haberkorn U; Eisenhut M; Mier W
    Nucl Med Biol; 2004 Jan; 31(1):21-30. PubMed ID: 14741567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.